Establishing a pre-clinical growing animal model to test a tissue engineered valved pulmonary conduit by Knirsch, Walter et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Establishing a pre-clinical growing animal model to test a tissue
engineered valved pulmonary conduit
Citation for published version:
Knirsch, W, Krüger, B, Fleischmann, T, Malbon, A, Lipiski, M, Lemmers, RFH, Sauer, M, Cesarovic, N,
Dave, H, Hübler, M & Schweiger, M 2020, 'Establishing a pre-clinical growing animal model to test a tissue
engineered valved pulmonary conduit', Journal of thoracic disease. https://doi.org/10.21037/jtd.2019.12.70
Digital Object Identifier (DOI):
10.21037/jtd.2019.12.70
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of thoracic disease
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2020;12(3):1070-1078 | http://dx.doi.org/10.21037/jtd.2019.12.70
Introduction
While mechanical or biological valve prosthesis are 
standard of care in adults requiring surgical replacement of 
heart valves, the surgical repair in children with congenital 
heart disease (CHD) has specific requirements for valve 
replacement. This includes small valve diameters with the 
potential to grow, and specific tissue properties related 
to age-dependent immunological and degenerative tissue 
reactions. However, all current used valve substitutes 
have significant limitations with need for permanent 
anticoagulation in mechanical prosthesis, potential risk of 
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infection, calcification and structural valve degeneration 
(SVD) in biological prosthesis, leading to reoperation. 
In different types of CHD such as common arterial trunk, 
pulmonary atresia with ventricular septal defect, or patients 
undergoing a Ross procedure, there is a high demand for 
a long-lasting connection from the right ventricle (RV) to 
the pulmonary artery (PA) with an integrated valve. Since 
the introduction of valved conduits as RV-PA connections 
in 1966 (1), its use has gained in popularity. Nowadays, 
the most used RV-PA conduits in CHD are cryopreserved 
homografts or bovine jugular vein conduits (Contegra®) (2). 
While early results for bovine jugular vein conduits are 
satisfactory with freedom from reoperation of 91% at 1 year 
and 84% at 2 years (3), at long-term follow up, there is a 
high risk for calcification and SVD which may be related 
to a stronger immunologic response during childhood (4). 
While blood-group compatibility seems to play a role for 
cryopreserved homograft implants (5), the rate of SVD for a 
homograft is similar to a bioprosthetic valve approximately 
30% after 10 years and 59% after 15 years (6). Overall, 
there are no evident differences between those two grafts on 
long-term follow up (2). 
The concept of regenerative medicine using a de-
cellularized porcine small intestinal submucosa extracellular 
matrix (ECM) biologic scaffold may overcome these 
limitations. Promising aspects exist with the development 
of tissue-engineered (TE) heart valves with an appropriate 
and sustaining hemodynamic profile, low thrombogenic 
potential and the potential to grow (7). Due to the 
high demand for valved RV-PA-conduits in congenital 
heart surgery we evaluated a self-constructed TE valve 
(CorMatrix® Cardiovascular, Inc., USA) in orthotopic RV 
to PA position in a growing large animal model. 
Though the use of ovine model for heart valve 
replacement is not novel (8-10) here we like to share 
our set-up and highlight differences to other protocols. 
Likewise, we want to share how we constructed the conduit 
out of a commercially available patch which could also be 
useful in clinical practice. 
Study rationale
To test a TE valved conduit in orthotopic pulmonary 
position which should be physiological, durable and has 
the potential for growth. In a step-by-step approach, we 
first self-created a valved conduit out of a commercially 
available TE patch and developed an adopted surgical 
implantation technique to lower peri- and postoperative 
mortality. Second, we established a chronic animal model 
as proof of feasibility, followed by a proof of concept, 
resulting in a chronic (2-year) follow-up study. The animal 
model should clarify, whether the valved pulmonary conduit 
function determined by echo remains stable and grows 
during the follow-up period, and finally whether TE patch 
material will be replaced resp. colonized by host tissue on 
histological examination after autopsy.
Creating a valved conduit
A de-cellularized porcine small intestinal submucosa ECM 
biologic scaffold (Cormatrix® Patch) served as the basis for 
the RV to PA valved conduit. For the first experiments, the 
company (CorMatrix® Cardiovascular, Inc., USA) provided 
uniquely produced valved conduits with a standardized 
diameter of 20 to 24 mm. Later we changed to a more 
tailored approach: the conduit was self-constructed out of a 
commercially available ECM scaffold (10 cm ×7 cm; four-
layers) according to the size of the pre-operatively measured 
pulmonary valve annulus (see also operative technique). 
The longitudinal side was divided in three equal parts 
mimicking the later created commissures. A ratio of 1:1.2 
was established between the conduit diameter and the leaflet 
height (e.g., for a 20 mm diameter conduit the leaflets high 
was 24 mm). In each leaflet a “dome” was created from the 
commissure attachments toward the middle of the leaflet 
(approximately 2 to 4 mm in height; Figure 1A). The leaflet 
part was then folded (Figure 1B). The attachments of the 
commissure were enforced with a 6-0 pledged Prolene 
suture in Z technique (Figure 1C). Finally, a conduit 
was formed with a double running suture (Prolene 6-0; 
Figure 1D). The final length of the valved conduit was 
tailored accordingly to the length of the resected pulmonary 
trunk. It was carefully ensured that the conduit was at least 
a few centimeters longer than the leaflet height to avoid 
incorporation of the leaflets into the distal suture line. The 
final conduit may be seen in Figure 2. 
Operative technique
For the procedure 23 female Swiss White Mountain lambs 
(27–38 kg, ±3.6 SD) were anesthetized by board certified 
veterinary anesthesiologists (outcome may be seen Table 1). 
Following the establishment of venous access via the 
internal jugular vein, general anesthesia was induced 
with a combination of ketamine (4 mg/kg, iv), midazolam 
(0.5 mg/kg, iv) and propofol (2–5 mg/kg, iv) and, after 
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endotracheal intubation, maintained with isoflurane 
(1.0–2.0 vol% endtidal). Perioperative analgesia comprised 
of a continuous infusion of fentanyl (10 µg/kg/h, iv) 
supplemented by boli of fentanyl (1–2 µg/kg, iv) at the 
discretion of the attending anesthesiologist. Additionally, 
local anesthesia with ropivacain (2–3 mg/kg, sc) was 
performed at the incision site prior to and after surgery. 
Monitoring included continuous electrocardiogram 
(ECG), transcutaneous hemoglobin oxygen saturation 
(SpO2), invasive blood pressure via the femoral artery 
and an ear artery, central venous pressure via the internal 
jugular vein, urine output by a bladder catheter and 
body temperature by a rectal temperature probe. Before 
start of surgery measurement of lactate dehydrogenase 
(LDH), hemoglobin (HB), hematocrit (HCT) and white 
blood cell count (WBC) were performed. During and 
after surgery, blood gas analysis was performed regularly 
and serum electrolytes perioperatively supplemented, as 
required. Lidocaine 1% (3 mg/kg/h, iv) was continuously 
administered as an antiarrhythmic drug during heart 
manipulation. Perioperative antibiotic prophylaxis consisted 
of penicillin (35,000 IU/kg, iv) and gentamycin (4 mg/kg, 
iv) which was continued until postoperative day five. All 
sheep were provided with a subcutaneous injection of a 
tetanus vaccine (Tetanus-Serum Intervet, MSD Animal 
Health; Switzerland). Transesophageal echocardiography 
(TEE) was performed preoperatively to determine the 
diameter of the pulmonary annulus and exclude structural 
heart abnormalities. For the operation the animals were 
placed in a lateral position. Surgical access was carried out 
via a left lateral thoracotomy (LLT) in the 4th intercostal 
B
D
A
C
Figure 1 Creation of a valved conduit using a commercially available tissue-engineered (TE) patch. (A) The patch was divided into three 
equal parts and leaflet height was marked including a doming on top. (B) The patch was folded creating three leaflets. (C) The created 
commissures were fixed using a 6-0 pledged Prolene suture. (D) Finally, the patch was formed to a conduit and closed using a double-
running suture line. 
Figure 2 The final conduit created prior to implantation showing 
the three leaflets. 
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space, without the removal of a rib. The pericardium was 
opened by protecting the phrenic nerve and stay sutures 
were placed. The pulmonary trunk was exposed and 
dissected. The implantation of the valved conduit was 
performed by use of cardiopulmonary bypass (CPB) without 
aortic clamping or application of cardioplegia (beating 
heart). Heparin (5,000 IU, iv) was administered before start 
of the CPB to establish an activated clotting time (ACT) 
greater than 300 seconds, which was maintained throughout 
the CPB period. The bloodless CPB machine priming 
included an additional 5,000 IU of heparin. The ACT 
was measured every 15–30 minutes throughout the CPB 
period and additional heparin boluses were administered 
as required. Arterial cannulation for CPB was established 
via the descending aorta using a 14-French cannula and 
venous cannulation via the right atrium using a single 
stage 30-French cannula. Once on CPB, mild hypothermia 
(35 ℃) was targeted and the native pulmonary valve and the 
complete pulmonary trunk were resected (Figure 3). Stay 
sutures were placed in the native pulmonary valve anulus at 
Table 1 Short-term outcome of the 23 sheep operated on
Animal number Weight (kg) Diameter conduit Outcome* Reason for death
1 30 24 Acute trial –
2 30 24 Acute trial –
3 32 20 Acute trial –
4 33.5 20 Acute trial –
5 33 20 Survived –
6 30 20 Survived –
7 29 20 Died peri-operatively –
8 27 18 Died in the OR Diffuse bleeding intra-operatively
9 24 18 Died peri-operatively Bleeding from femoral artery after removal of arterial line in  
the stable
10 27 20 Survived –
11 35 20 Died peri-operatively Low cardiac output postoperatively
12 35 20 Survived –
13 32 18 Died in the OR Pre-op restricted LV function; not weaning from CPB not 
possible
14 33 18 Survived –
15 36 20 Survived –
16 34 18 Survived –
17 38 18 Survived –
18 36 22 Died peri-operatively Found dead in stable after POD 1 (no reason found)
19 30 18 Died peri-operatively Pericardial tamponade with re-operation but died one day later 
due to low protein level in blood without possibility to transfuse
20 30 18 Survived –
21 28 18 Died in the OR Weaning from CPB not possible
22 28 18 Survived –
23 29 18 Survived –
Marked animals survived the operation and peri-operative phase. *, survived: mobilized and send to lawn, died peri-operatively: survived 
operation and was extubated, mobilization not possible and died within 2 days of operation. LV, left ventricle; POD, postoperative day.
1074 Knirsch et al. Pre-clinical growing animal model to test TE valved pulmonary conduit
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2020;12(3):1070-1078 | http://dx.doi.org/10.21037/jtd.2019.12.70
the edges of the three commissures to preserve the original 
valve orientation. The substitute was then implanted using 
a running suture (6-0 polypropylene) following the origin 
of the explant line (Figure 4) and orientated according to 
the stay sutures and the mounting of the leaflets within the 
conduit to achieve an accurate geometry. The suture line 
of the conduit pointed cranial/aortal for better bleeding 
control (Figure 5). After completing the distal anastomosis 
with a running suture (6-0 Prolene) the animals were 
weaned from CPB. Protamine (2,500 IU in 100 mL NaCl, 
iv) was administered under close observation of ACT until 
levels were below 300 seconds. Finally, after controlling 
major sources of bleeding, a chest tube was placed, and 
chest closure performed followed by a postoperative TEE. 
The final result of the implantation is available in Video 1. 
Postoperative care
After surgery, the sheep were positioned in dorsal 
recumbency and closely monitored during recovery from 
anesthesia. All animals received external heat support 
(warming blanket, Bair HuggerTM), warmed fluids and 
electrolyte supplementation (e.g., Mg, Ca, K) as needed. 
The thoracic drainage tube was evacuated regularly and 
removed shortly before removal of the endotracheal 
tube. After extubation, 100% oxygen was provided via 
a nasal mask. Each sheep was kept in the recovery area 
until respiratory rate, SpO2 and core body temperature 
were within the normal range, and the animal was able 
to maintain pink mucous membranes under ambient 
air conditions. For post-operative analgesia methadone 
(0.2 mg/kg, iv) was administered up to 3 days and 
metamizole (20 mg/kg, iv) up to 5 days. Carprofen (4 mg/kg, 
iv) was given at the end of the operation and once per day 
for up to 7 days, as needed.
Before transporting the animals back to the stable, both 
arterial catheters, one of the two jugular catheters and the 
urinary catheter were removed. The jugular venous catheter 
was protected with a bandage and remained in place for 
5 days, to allow for regular blood electrolyte analysis and 
intravenous drug administration. In the stable, the animals 
were kept in a single compartment for intensive care, but 
with nose-to-nose contact to companions. A warming lamp 
was used to facilitate recovery. Postoperative care continued 
until the animals were able to stand without ataxia and were 
starting to eat and drink.
All animals received acetylsalicylic acid (100 mg, po, once per 
day) for a total of 5 days. Antibiotics (Penicillin 35,000 IU/kg 
twice a day, iv and gentamycin 4 mg/kg once a day, iv) 
were administered for up to 5 days after surgery. Intensive 
care was provided for at least 5 days following surgery, 
depending on the state of the animal. Each sheep received 
Figure 3 The native pulmonary valve leaflets as well as the 
complete pulmonary trunk were resected.
Figure 4 After correct orientation the valved conduit was 
implanted using a running suture. 
Figure 5 The image shows the implanted valved conduit with 
the suture line of the conduit pointing cranial-aortal for better 
bleeding control. 
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at least twice daily a full clinical examination, including 
physical exam, observation of surgical site, assessment of 
attitude, activity, appetite, fecal and urine production, vital 
parameters (body temperature, pulse rate, respiratory rate), 
heart auscultation and assessment of potential signs of pain 
or reduced well-being. Blood electrolyte analysis and ACT 
were performed twice per day or when deemed necessary. 
If an animal appeared weak or lethargic, suggesting 
cardiovascular or respiratory compromise, further 
examinations were performed including echocardiography 
under general anesthesia. 
From the fifth postoperative day on, the animals received 
a full clinical examination once daily. Around this time, all 
sheep usually were in a stable condition and could be re-
socialized with their companions, without further need of 
medication or intensive care.
In every animal a routine follow-up echocardiography 
was performed in general anesthesia within the first month 
after surgery.
After verification of functionality of the conduit, all 
animals were transported back to the farm of the vendor for 
long-term husbandry and surveillance (clinical check at least 
three time a week). Thereafter, the animals were brought 
back only for the scheduled routine follow-up controls or 
in case of pathological signs during the routine clinical 
examinations on the farm.
Echo protocol
Transesophageal (TEE) and transthoracic (TTE) two-
dimensional Colour-Doppler echocardiography were 
used to evaluate cardiac function and the structure 
and functionality of the implanted RV-PA-conduit 
intraoperatively and during follow-up controls. All 
examinations were realized under general anesthesia and 
were performed by pediatric and/or adult TEE/TTE-
certified personnel on a Philips iE33 ultrasound machine 
(Philips Center, Amsterdam, The Netherlands) by use 
of a 7-2 MHz multiplane echo probe (Philips X7-2t) for 
TEE and a 5-1 MHz echo probe (Philips S5-1) for TTE. 
We evaluated the morphologic (thickness, mobility, and 
potential calcification of valve leaflets) and functional (valve 
stenosis and regurgitation) appearance of the valved RV-
PA-conduit. This included measurements of the diameter 
at a sub-valvular, valvular and supravalvular level and of the 
maximal systolic and mean pressure gradient using pulsed 
and continuous-wave Doppler. Valvular regurgitation of the 
pulmonary conduit was quantified using Colour Doppler 
and retrograde directed pulsed-wave Doppler signals in 
the main PA and main side branches. The aortic valve was 
monitored in comparison to the valved pulmonary conduit. 
Right ventricular (RV) function was qualitatively evaluated 
by eyeballing and categorized as normal, moderately or 
severely impaired. The RV size was evaluated by measuring 
the diameter of the tricuspid valve annulus, the inflow tract, 
ventricle, and outflow tract in a standardized view in TTE 
(Figure 6A,B). 3-D Echocardiography to reconstruct the 
pulmonary valve was done as well (Figure 6C). Tricuspid 
valve regurgitation was evaluated by Colour Doppler.
Follow-up protocol
Follow-up controls included a clinical, laboratory and 
echocardiographic examination and were scheduled at 
regular time intervals: once within the first post-operative 
month, at 3, 6, 9, 12, 18 and 24 months. For each of these 
controls, the animals were transferred back from the farm 
to the Division of Surgical Research. Growth and thriving 
were monitored by body weight. Laboratory checks for 
hemolysis and infection included measurements of lactate 
dehydrogenase (LDH), hemoglobin (HB), hematocrit 
(HCT) and white blood cell count (WBC). At the end 
of the study period, the RV-PA-conduit was evaluated 
for calcification by a CT scan followed by thorough 
pathological evaluation after scarification of the animal. 
Macroscopically cardiac examination was performed both 
in-situ and following removal of the intact heart. The 
chambers of the heart were opened along the path of blood 
flow to allow a full visual assessment. The PA (both native 
and conduit) was opened longitudinally, cutting at the valve 
commissure to preserve the integrity of the leaflets. All steps 
were photographic documented including a video clip of the 
still beating heart when the conduit was free from adhesions. 
The entire heart was fixed in 10% neutral buffered formalin 
before cutting in the tissues for processing. Each valve was 
bisected so that each tissue section included the center 
of the valve leaflet and the proximal and distal junctions 
of the conduit. After a minimum of 24 hours fixation, 
tissues were routinely processed through a graded series 
of alcohol, embedded in paraffin and sectioned at 2 μm for 
haematoxylin and eosin staining. 
For a subset of the valves, consecutive sections were 
mounted on standard or positively charged slides and used 
for special staining or immunohistology respectively. The 
panel included the special stains Masson’s trichrome, Elastic 
Van Gieson, and Von Kossa, and the immunohistological 
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markers alpha smooth muscle actin (smooth muscle), CD31 
(endothelial cells), Ki-67 (proliferation marker), caspase 3 
(apoptosis), and CD68 (cells of monocyte lineage).
Comments
So far, most studies in animals using the Comatrix patch as 
complete or partial valve substitute have a mid-term follow 
up of three to eight months (11-14). There are hints that 
more long-term data from animal trials are needed as there 
seems to be doubt about mid-term outcome using this 
material for valve substitutes (15). Therefore, we established 
a growing animal model to evaluate a TE valved conduit. 
The use of ovine model for heart valve replacement has been 
reported but mostly in adult sheep (8) or a shorter follow up 
(9,10). To the authors knowledge this is the first description 
of a lamb model aimed on a long-term outcome reaching a 
follow up time of 2 years. Likewise, importantly, we were able 
to self-construct the valved conduit out of a commercially 
available patch already used in clinical practice.
From our experience and study set-up we would like to 
share some key findings to reinforce the importance and 
validity of detailed study protocols. 
(I) The advantage of a sheep model relies on anatomical 
and hemodynamic similarities compared to 
human physiology, e.g., the molecular basis of 
cardiac contraction, the coronary anatomy and the 
hemodynamic profile of the pulmonary arteries (16). 
Compared to a human, structural changes and 
calcification of a cardiac valve (primary outcome 
parameter) occurs much earlier in an ovine. 
Because 1 year of a sheep life roughly equals 7 years 
of a human’s life ‘long-term’ outcome results may 
be acquired in shorter time periods (ratio 1:7);
(II) From other pre-clinical experiments using off-the-
shelf de-cellularized TE patches (17,18) as aortic 
valve leaflet (19) we learned that the potential 
benefits of a thoracotomy outweighed those of a 
sternotomy, especially when considering a chronic 
study. According to our experience using a LLT via 
the fourth intercostal space (i) offers good exposure 
to the pulmonary trunk and the pulmonary valve, (ii) 
allows reliably the cannulation of the descending 
aorta and the right atrium via the right auricle 
and (iii) promotes early extubation and sufficient 
spontaneous breathing as postoperative pain is 
diminished in these animals  normally lying on the 
sternum;
(III) The exposure of the ascending aorta, clamping and 
infusion of cardioplegia is technically challenging 
in sheep due to the short size of the ascending 
aorta. We have experienced that the avoidance 
of cardioplegia overweighs the inconvenience to 
perform the valve implantation in beating heart 
conditions;
(IV) Hemolysis is one of the potentially serious 
complications of prosthetic heart valves and is 
usually associated with structural deterioration. Only 
sparse reference values are available in the sheep 
model. To gain more data about this important issue, 
we suggest to monitor the values of relevant blood 
hemolysis parameters (LDH, Hb) over time;
(V) A proper evaluation of the implanted valve and the 
heart function requires a combined transesophageal 
and transthoracic examination which can be done 
in a short-duration general anesthesia. During 
B CA
Figure 6 For routine follow-up visits the valved conduit was evaluated by means of transesophageal and transthoracic echocardiography 
(TTE) using standardized views. (A-C) Here an example of a 1-year follow-up examination; yellow arrow pointing toward pulmonary valve 
leaflets. The images show TTE for measuring RV size at the inflow tract, ventricle, and outflow tract as well as diameter of the tricuspid 
valve annulus. RVOT, right ventricular outflow tract; PA, pulmonary artery.
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the scheduled examinations we did not lose any 
animal due to hemodynamic impairment caused 
by anesthesia. Nevertheless, we recommend the 
examination being performed by certified and 
experienced personnel to obtain good quality 
imaging in the shortest amount of time to limit the 
duration of general anesthesia.
We believe that failure to make a detailed study protocol 
for such extensive animal experiments may result in 
important limitations at the end of the study and effect 
animal welfare in a negative way. Our experiences and 
comments may help other groups using a sheep model in 
cardiovascular disease research to improve survival rates and 
increase animal welfare. 
So far, most studies in animals using the Comatrix 
patch as complete or partial valve substitute have a three to 
6 months follow-up. We believe that more long-term data 
(>12 months follow-up) is needed.  
Limitation
So far there is no sufficient evidence that CorMatrix® tissue 
can grow. Some recent clinical studies show that the patches 
are prone to calcification and failure. The used patches here 
were not seeded with live autologous cells. Although it would 
have been interesting to test conduits with smaller diameters 
none of our animal had a pulmonary valve annulus below 18 
mm and we did not want to undersize the conduit. 
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